Overview

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

Status:
RECRUITING

Trial end date:
2032-02-01

Target enrollment:

Participant gender:

Summary

The main purpose of this study is to assess if olomorasib in combination with pembrolizumab is more effective than the pembrolizumab and placebo combination in part A in participants with resected KRAS G12C-mutant NSCLC and to assess if olomorasib in combination with durvalumab is more effective than the durvalumab and placebo combination in part B in participants with unresectable KRAS G12C-mutant non-small cell lung cancer. The study may last up to 3 years for each participant.

Phase:

PHASE3

Details

Lead Sponsor:

Eli Lilly and Company

Collaborator:

AstraZeneca

Treatments:

durvalumab
pembrolizumab